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Abstract
DegP, a member of the HtrA family of proteins, conducts critical bacterial protein quality control by both chaperone and
proteolysis activities. The regulatory mechanisms controlling these two distinct activities, however, are unknown. DegP
activation is known to involve a unique mechanism of allosteric binding, conformational changes and oligomer formation.
We have uncovered a novel role for the residues at the PDZ1:protease interface in oligomer formation specifically for
chaperone substrates of Chlamydia trachomatis HtrA (DegP homolog). We have demonstrated that CtHtrA proteolysis could
be activated by allosteric binding and oligomer formation. The PDZ1 activator cleft was required for the activation and
oligomer formation. However, unique to CtHtrA was the critical role for residues at the PDZ1:protease interface in oligomer
formation when the activator was an in vitro chaperone substrate. Furthermore, a potential in vivo chaperone substrate, the
major outer membrane protein (MOMP) from Chlamydia, was able to activate CtHtrA and induce oligomer formation.
Therefore, we have revealed novel residues involved in the activation of CtHtrA which are likely to have important in vivo
implications for outer membrane protein assembly.
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Introduction
Chlamydia (C.) trachomatis is the etiological agent for the most
prevalent bacterial sexually transmitted infection world-wide. The
microorganism is an obligate intracellular bacterium, which is
estimated to have diverged to the intracellular niche from a
common ancestor some 750 million years ago [1]. Consequently,
the chlamydiae have evolved a reduced genome of around 1000
protein coding genes, which has resulted in novel modifications of
conserved bacterial proteins [2]. C. trachomatis HtrA (CtHtrA), the
chlamydial ortholog of Escherichia (E.) coli DegP [3,4], is a member
of the HtrA (High temperature requirement protein A) protease
family, which are widely conserved among single and multicellular
organisms [5]. In well characterised bacterial systems, DegP has
been shown to be essential for virulence, and has been implicated
in virulence factor secretion such as the filamentous haemagglu-
tinin of Bordetella pertussis [6]. CtHtrA is upregulated during
Chlamydia persistence disease models and stress conditions [4,7],
which is consistent with an important role in the Chlamydia life
cycle. Whether CtHtrA is essential for Chlamydia viability and
virulence has not been definitively established, however, as there
are currently no molecular tools to generate gene deletions or
complementations in Chlamydia. As with DegP in other bacterial
systems, CtHtrA is an attractive target for antimicrobial drug
design.
DegP conducts bacterial stress responses and virulence functions
that are specifically associated with protein quality control [8,9]
(reviewed, [10]). While the DegP protease activity recognises and
degrades misfolded and mislocalised proteins, the chaperone
activity promotes correct folding or refolding of denatured
proteins, prevents unwanted aggregation and protects outer
membrane proteins from degradation by other proteases during
their passage through the periplasm [11]. The ability to conduct
both proteolysis and chaperone activity to maintain protein quality
ensures this protein is often essential for bacterial pathogenesis
[12,13].
DegP proteases utilise a unique mechanism of allosteric
regulation that involves both conformational and oligomeric
changes [14]. All members of this family have a serine protease
domain with a chymotrypsin fold (S01) in the PA clan (MEROPs
database) [15] and either one or two C-terminal PDZ (PSD-95/
Dics-Large/ZO-1) domains [16]. The mechanism of DegP
proteolysis activation involves a cascade of allosteric activation,
conformational rearrangement, and oligomerisation. The protein
‘rests’ as an inactive hexamer, in which the proteolytic active site of
each monomer is occluded by the extended LA loop of an opposite
monomer [17]. Unfolded protein substrates or small hydrophobic
peptides bind to the activator cleft in PDZ1 and induce
rearrangement of the protease to a proteolytically active trimer.
Structural rearrangements involved in activation include loop
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rearrangement surrounding the active site and subsequent
oligomerisation of the trimer to proteolytically active 12-mer and
24-mer complexes [18,19]. Assembly into large oligomers is also
thought to be the mechanism by which DegP is able to chaperone
ß-barrel proteins in their fully folded conformation during
transport to the outer membrane in Gram negative bacteria [20].
The ability to differentially respond to the substrates which
require either chaperone or proteolysis activity is one of the
hallmarks of this unique protein. Yet, the DegP components which
control and mediate between these two distinct functions remain
to be identified. In this work we demonstrated distinct oligomeric
responses when CtHtrA proteins with mutations in either the
PDZ1 activator cleft or the PDZ1:protease interface were
activated. These distinctions were dependent on whether the
activator was a peptide or a protein chaperone substrate.
Results
CtHtrA prefers to cleave sequences with non-polar
residues at P1
To analyse the substrate sequence specificity, CtHtrA was
screened against two peptide libraries and then kinetic analysis was
conducted against specific peptide sequences. Initial CtHtrA
proteolysis screening against an endopeptidase derived GluC
PICS peptide library [21] identified a total of 85 cleavable peptide
sequences, with a preference for non-polar amino acids on both
the prime and non-prime sites (Fig. 1, Fig. S1A, and Fig. S1B).
Analyses using the GluC library illustrated a preference for I/A/V
in P1 and G/A in P19. No peptides with L at P1 were identified
although L was frequently identified at P29 and P39. L was most
frequently identified at P2, although there was a greater variety of
residues identified at P2 compared to P29 and P39.
To further refine the CtHtrA substrate specificity, the REPLi
peptide library (Mimotopes, Melbourne) was screened. The
REPLi library peptides consist of a randomised tripeptide
sequence flanked on either side by two GGG tripeptide sequences.
The N-terminus of each peptide was labelled with a 7-
methoxycoumarin (MCA) fluorophore, and the C-terminus was
labelled with a 2,4-dinitrophenyl (DNP) fluorescent quencher. The
peptides were pooled according to structural similarity and
selected wells with high activity were then rescreened as individual
peptides to identify the peptides cut by CtHtrA (Fig. S2, all wells
where CtHtrA activity was observed). The cleaved peptides always
had at least one hydrophobic residue (I, L, A, V, or P) in the
variant trimer sequence (Table 1). Cleavage at the glycine or
terminal fluorophore or quenchers was never detected for any
peptide. Where peptides had either an I or L at the same site in the
variant sequence, there was always higher cleavage rates with I.
A series of peptide substrates were then designed based on the
cleavage sites previously identified in ß-casein [3], PICS results,
previously published substrates for E. coli DegP [22], and the
REPLi library screening results. These peptides were assayed
against CtHtrA and kinetic analysis was conducted (Table 2). The
‘best’ CtHtrA substrate was MFKLI-pNA (Kcat/Km=1084.8).
The data suggests that I was the most preferred residue in the P1
site, with V and L the next preferred residues for P1. However the
activity does not depend solely on the residue at P1 with at least
P2-P4 also influencing the activity. As the most preferred P1
residues; V, T, and I all have beta-methyl groups, this also suggests
an unusual preference for beta-branched amino acids at P1 site.
Generally, peptides with only 4 residues or less were not cleaved.
FKLI-pNA was the only four residue peptide that was cleavable by
CtHtrA. The preference for K at P3 implies a salt bridge may be
involved in substrate coordination in the CtHtrA active site in the
substrate pocket or subsite S3. In a direct comparison between
MFRLI-pNA and MFQLI-pNA, R was clearly the most preferred.
MFRLI-pNa exhibited a ten-fold higher Vmax, which is consistent
with the residue at the P3 site being involved in a salt bridge that is
important for substrate binding. The Km for each of these,
however, was at least an order of magnitude higher than the Km
for MFKLI-pNa. The results from individually synthesised
peptides (Table 2) and the peptides sourced from the REPLi
library (Table 1) were consistent in that non-polar sequences are
most preferred. MCA-IRRVSYSF-DNP, a peptide based on the
optimal activity for human HtrA2 [23] was not a viable substrate
for CtHtrA (data not shown). Two cleavage sites were observed in
the peptide based on a ß-casein cleavage site (MCA-EN-
LHLPLPIIF-DNP, Bcas1) when analysed by LC-MS-MS
Figure 1. Heat map of CtHtrA peptide cleavage sites identified
by PICS. Summary of all PICS data (raw data is shown in Fig. S2). The
colour key is indicated below the figure. The relative position in the
peptides is indicated at the top and each residue is listed to the left.
doi:10.1371/journal.pone.0024547.g001
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(MCA-ENLHQLPLPIQIF-DNP), one was not a site previously
identified in the full length ß-casein assay [3] (Fig. S3).
CtHtrA protease activity can be increased in rate by the
presence of an activator peptide
To determine if the addition of a second peptide to the protease
assays could activate or increase CtHtrA proteolysis, two activator
peptides were tested in the CtHtrA cleavage of the model ß-casein
peptide substrate Bcas1. The first was based on the ß-casein C-
terminal sequence (Act1: NH2-VLGPVRGPFPIIV-OH) and the
second on insulin b chain C-terminal sequence (Act2: NH2-
CGELGFFYTP-OH). Both of these proteins are known to be in
vitro substrates of CtHtrA, hence their C-terminal sequences may
be involved in activation of CtHtrA [3]. The ß-casein C-terminal
based activator peptide (Act1) showed the greater ability of the
two activators to increase the proteolysis rate (Fig. 2). Following
this result, the proteolysis rates of other known CtHtrA substrates
was then monitored in the presence of Act1. Not all substrates
were cleaved at a faster rate in the presence of the activator
peptide (Fig. 3); and in general, the pNA substrates showed no
difference in rate. No evidence of Act1 cleavage by CtHtrA could
be detected when examined by MALDI MS MS (data not shown).
One explanation for the observation of a lack of activation for some
substrates could be that these substrates act as both activators and
substrates by binding to both the active and allosteric sites of CtHtrA.
In particular, the pNA peptides were not activated, which could imply
that the pNA moiety itself may bind at the activation site. In order to
test this possibility, a peptide (QNIPF) with an F which has as similar
structure to the pNA but lacks the nitro-group, was tested as an
activator. This peptide activator did not activate CtHtrA cleavage of
Bcas1 but did activate the cleavage of some of the pNA peptides tested
(data not shown). This supports the hypothesis that at least some pNA
substrates can act as both activators and substrates.
To assess if the presence of the activator peptide alters the
substrate specificity, the role of the Act1 activator was further
examined using PICS library screening. The addition of the
activating peptide increased the observed frequency of V and I in
P1 and A in P19 (Fig. 3), but did not alter the specificity. The
presence of the activating peptide increased the number of
identified peptides (90) compared to the non-activating peptide
assay (85) (Fig. S4A and Fig. S4B).
CtHtrA PDZ1 carboxyl terminal binding cleft has a role in
activation and substrate specificity
The hexameric CtHtrA molecular model was examined to
identify the putative PDZ1 activator binding cleft (Fig. 4). The
Table 1. Peptide sets tested from selected positive wells
REPLi library.
Peptides1 Dfluorescence2 Peptides1 Dfluorescence2
LLA 0 IAF 1.344 (0.14)
LLV 1.9 (0.10) IAY 0.41 (0.043)
ISF 3.9 (0.30) IVF 0.19 (0.016)
ISY 2.84 (0.06) IVY 0
ITF 0 LAF 0
ITY 0 LAY 0
LSF 0 LVF 0
LSY 0 LVY 0
LTF 0 ASF 0.282 (0.029)
LTY 0 ASY 0
IIA 0.6 (0.02) ATF 0
IIV 0 ATY 0
ILA 0.403 (0.07) VSF 0.92 (0.043)
ILV 2.2 (0.03) VSY 1.77 (0.099)
IFA 0.41 (0.09) VTF 0.263 (0.016)
IFV 0.6 (0.08) VTY 0
IYA 0
IYV 0
1Each peptide consists of a variant trimer (as listed in the column) between
consistent trimers of glycine with a flourophore and quencher (MCA-GGG XXX
GGG-DNP).
2min21 mg CtHtrA21 mean and (standard deviation).
doi:10.1371/journal.pone.0024547.t001
Table 2. Peptide substrates of CtHtrA.
Substrate Source of peptide
Vmax (mM sec21, mM
CtHtrA21) Km (mM) Kcat/Km (M21 s21)
DPMFKLV-pNA E. coli substrate [22] 4.678 0.0003233 241.2
DPMFKLP-pNA Model E. coli substrate
P at P1
2.917 0.003874 159.8
DPMFKLL-pNA Model E. coli substrate
L at P1
3.179 0.0008829 763.3
DPMFKLI-pNA Model E. coli substrate
I at P1
10.340 0.0005271 32.7
PMFKLI-pNA 1 residue less 9.931 0.0003142 526.7
MFKLI-pNA 2 residues less 4.046 0.00006204 1084.8
FKLI-pNA 3 residues less 0.9723 0.0005740 28.2
DMPFKLT-pNA Model E. coli substrate
T at PI
8.955 0.0009404 158.7
DPMFKQT-pNA Model E. coli substrate
change P1 and P2
0.3165 0.000009381 542.2
MFRLI-pNA P3 modification 18.53 0.002908 106.22
MFQLI-pNA P3 modification 0.1796 0.0001409 21.2
doi:10.1371/journal.pone.0024547.t002
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base of this cleft in CtHtrA is a hydrophobic pocket formed by the
residues L302 and I365 (V328 in E. coli DegP) (Fig. 4). L302 and
I365 were targeted for site directed mutagenesis (L302N and
I365D) to make this non-polar pocket either polar or charged. The
role of a potential conformational change caused by movement of
the whole PDZ1 domain relative to the protease subunit was also
tested by mutating a highly conserved arginine residue (R299W)
on the flexible loop between the protease and PDZ domains [24].
This mutation was made in order to alter the flexibility around this
residue while occupying a similar sized area. Additionally, a
second mutation was made in conjunction with the R299W
mutation on the residue R373A which potentially forms a salt
bridge between the PDZ domain and protease domain. This
double mutation was made in order to reduce the flexibility and
disrupt the mobile salt bridge involved in the PDZ1:protease
domain interface. The R373A mutation was also made indepen-
dently of R299W. These mutated proteins were assayed to
examine the impact of the changes on Act1 activation on the
Bcas1 substrate proteolysis. The R299W and L302N mutations
drastically reduced the protease activity on Bcas1 to below the
limits of detection in this assay. The I365D, R373A, and R299W/
R373A mutations all retained the ability to cleave Bcas1,
although at a markedly reduced rate compared to the CtHtrA
wild-type (Fig. 4C). Interestingly, while R299W was inactive in this
assay; the activity was somewhat restored by the R299W/R373A
combined mutation. Act1 failed to increase the proteolysis rate for
any of these three mutated proteins, indicating that these residues
are involved in the activation of proteolysis. The mutated proteins
were tested for protease activity against ß-casein. The L302N
CtHtrA mutant was unable to cleave ß-casein even after two hours
incubation, while the R299W, R3783A, I365D, R373A, and
R299W/R373A mutants were all active (data not shown).
CtHtrA is able to form large 24-mer multimeric
complexes which are impacted by mutations in the
activator cleft
E. coli DegP proteolysis activation involves the transition from
resting hexamers via trimers to 12- and 24-mers following the
peptide activator binding to the PDZ1 binding cleft [18]. CtHtrA
oligomer formation induced by Act1 addition was examined after
incubation for 10 mins at 37uC. The wild type and mutant
proteins were incubated with either the ß-casein based activator
peptide (Act1), or with whole insulin (intact), or in the absence of
any activator as a control. CtHtrA incubated in the absence of any
added activators formed 24-mers with some hexamers detected
after 10 mins (Fig. 5). The incubation of CtHtrA with Act1
induced the protein to form 24-mers after 10 mins (Fig. 5). In the
presence of insulin, CtHtrA was also activated to 24-mers with
little hexamer visible. The R299W mutant was present as hexamer
and 24-mer in the control with no activator. Low levels of 24-mer
were formed when R299W was incubated with Act1 and mainly
hexamer with insulin. The L302N mutant was not detected in any
higher oligomeric form under any conditions. L302N was detected
as faint hexamer and trimer but mostly monomer under all tested
conditions (not visible on these gels). R373A incubation with Act1
resulted in 24-mer formation. Conversely, R373A incubation with
insulin was mainly detected as hexamer. I365D was detected as
hexamers, trimers, 12-mers, and some 24-mers when incubated in
the absence of activators. In contrast, no 12-mers, but only
hexamers and 24-mers were detected when I365D was incubated
with Act1.
The R373A/R299W protein was mainly detected as hexamers
when not activated. Act1 induced R373A/R299W 24-mer
formation. This activation was very similar to that observed for
CtHtrA, and was the only condition during which any of the
mutated proteins oligomerised in a similar profile to CtHtrA. In
direct contrast, R373A/R299W did not form a similar profile of
oligomers as wild-type CtHtrA when incubated with insulin.
Recombinant chlamydial major outer membrane protein
(MOMP) and chlamydial outer membrane protein C-
terminal peptides can induce CtHtrA oligomerisation
The most likely in vivo candidates for the chaperone activity of
CtHtrA are outer membrane ß-barrels, which have been
previously identified for E. coli DegP [25]. The OMPdb outer
membrane ß-barrel database [26] identifies 13 outer membrane ß-
barrels in the C. trachomatis L2 genome. An alignment of these
shows the expected high homology of the C-terminal sequences
consisting of the recognition sequence for the outer membrane
protein assembly apparatus BamA (reviewed [27]). Co-incidental-
ly, the conserved hydrophobic residues for the BamA recognition
motif are consistent with the hydrophobic residues in the Act1 but
not Act2 (Fig. 6). This could imply that the C-terminal sequences
which stimulate CtHtrA oligomerisation are the same as those
required to direct the substrate to BamA to facilitate outer
membrane protein assembly. In order to test this possibility two
peptides corresponding to the C-terminal 13 residues of proteins
with this ß-barrel C-terminal sequence were tested for activation of
CtHtrA oligomerisation. The two peptides were from the outer
membrane ß-barrels PmpC and CtL0043 (PmpC: H-
LAHMMNCGARMIF-OH, CtL0043: H-AESNFKMLEIEAE-
OH). Additionally a control peptide based on the C-terminal
sequence of a soluble cytoplasmic enzyme pyruvate kinase was
Figure 2. CtHtrA protease activity can be activated by ß-casein
C-terminal based peptide (Act1) to greater rates than insulin b-
chain C-terminal based peptide (Act2). Rates of generation of
fluorophore (or cleavage of Bcas1 peptide releasing fluorophore from
quencher) per minute per mg of CtHtrA (y-axis) are higher for Act1. The
activators tested were Act1 (NH2-VLGPVRGPFPIIV-OH) based on the C-
terminal sequence of b-casein and Act2 (NH2-CGELGFFYTP-OH) based
on the C-terminal sequence of insulin (b-chain), with different
concentrations compared to the rate without any activator added
(x-axis).
doi:10.1371/journal.pone.0024547.g002
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tested (PyKinC: H-HDVLSPSLDEINVP-OH). Purified recombi-
nant C. trachomatis MOMP, the major outer membrane protein
with a maltose binding protein tag (MBP-MOMP) [28] and a
tryptic digest of the MBP-MOMP were also tested for CtHtrA
activation.
When CtHtrA was incubated with the tryptic digested MBP-
MOMP protein (MOMP peptides), much of the protein remained
present as a hexamer with only a minor amount of 24-mer visible
(Fig. 6). In contrast, when CtHtrA was incubated with the purified
whole MBP-MOMP, CtHtrA was mainly present as a 24-mer with
only a minor amount of hexamer visible. Thus the same protein
present as tryptic peptides or as full length protein had a
differential impact on triggering CtHtrA oligomerisation. The
incubation of CtHtrA with the three different C-terminal peptides
from C. trachomatis proteins all resulted in similar oligomer
formation with no 24-mer detected. The PmpC peptide activated
the formation of 12-mer. The CtL0043 and PyKinC peptides
activated mainly trimer formation with some 12-mer present
(Fig. 6). These data suggest that the specific sequence of the
peptide is important for the binding and subsequent triggering of
oligomerisation. Furthermore, it is not just the presence of the
consensus for outer membrane protein assembly of the peptide
that determines successful activation of CtHtrA oligomerisation.
Finally, in order to determine if the 24-mer (highest amount
with MOMP protein, or Act1), or 12-mer, or both, corresponds to
enhanced protease activity, the incubations of CtHtrA and these
potential in vivo activators were used for protease assays with the
Bcas1 substrate (Fig. 6). Incubation with the PmpC peptide did
not increase the rate of proteolysis of Bcas1. The incubation with
Act1, MBP-MOMP peptides, or MBP-MOMP protein resulted in
an increased proteolysis rate. The presence of the majority of
CtHtrA as higher order oligomers correlated with an increased
rate of proteolysis for CtHtrA, particularly when these oligomers
were predominately 24-mers.
Discussion
DegP is a remarkable protein which conducts proteolysis and
chaperone activities critical for pathogenesis, outer membrane
protein biogenesis, and stress survival for many bacteria. As the
most conserved and best understood member of the HtrA protein
family, the elucidation of DegP’s activation via allosteric regulation
and oligomeric formation of spheres and bowl like structure has
also contributed significantly to general understanding of protein
structure regulatory mechanisms [18,19,25,29,30]. Two DegP
structural forms are thought to mediate chaperone activity; lipid
associated bowls and oligomeric spheres [20,30]. Very recently the
lipid associated bowl form has been demonstrated to mediate
chaperone activity for one substrate for Bordetella [31], providing
evidence that these two structural models are relevant in vivo.
However, in spite of these advances it remains unknown how
Figure 3. Activation of CtHtrA cleavage of smaller pNA based
peptides by Act1 activator. A. pNA substrate cleavage represented
by the change in absorbance at 405 nm per mg CtHtrA per second (y-
axis). The substrates were tested with Act1 (NH2-VLGPVRGPFPIIV-OH
120 mM; grey) or without Act1 (black bar). B. Activation of CtHtrA
cleavage of flourimetric peptides by Act1. The Fig. shows the rate of
increase of fluorescence per mg CtHtrA (y-axis) for each of the peptides
(left to right: IAF, IAY, ASF, VSY, VTF), at 0, 12.2 mM Act1, and 120 mM
Act1. C. Heat map of peptide cleavage sites of CtHtrA as identified by
PICS in the presence of the Activator peptide (120 mM). The figure is a
summary of all the data in Fig. S4. The colour key is indicated to the
bottom of the figure. The relative position in the peptides is indicated
at the top and each residue is listed on the left side of the figure.
doi:10.1371/journal.pone.0024547.g003
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DegP differentially targets substrates for degradation or chaperone
activity. Our current study identified for the first time that
formation of CtHtrA oligomers triggered by chaperone substrates
requires the residues which form the interface between PDZ1
domain and the protease. Furthermore, we demonstrated that a
potential in vivo chaperone substrate, a major pathogenesis protein
(MOMP), triggered oligomer formation suggesting that CtHtrA
has a critical role in outer membrane protein assembly.
Generally, the preferred sequences for CtHtrA hydrolysis were
hydrophobic with non-polar residues found to be particularly
preferred at P1. The specificity of the protease activity did not vary
when a complex mix of peptides (PICS) or individual peptides
were present. The residues which were most preferred (generally
non-polar residues) were consistent with those likely to be only
accessible during protein unfolding or protein stress conditions.
CtHtrA had a preference for V/I/A at P1, which is somewhat
similar to elastase-2 [32]. While less specific, CtHtrA also showed a
preference for small hydrophobic residues (A/G/L) on the prime-
side of the active site P19, P39–P49.
CtHtrA proteolysis was able to be activated by the addition of a
second peptide. The proteins with PDZ1 activator cleft and
PDZ1:protease interface mutations were all defective for protease
activation indicating the activation involved allosteric binding to
PDZ1. This indicates that the PDZ1 activator cleft and
PDZ1:protease interface function in the activation of CtHtrA
proteolysis.
The activation of CtHtrA proteolysis was demonstrated to be
via the formation of higher order oligomers, predominantly a 24-
mer. The presence of some oligomeric CtHtrA, even in the
absence of activator, may imply that protein contaminants were
present in the purified protein. It is commonly reported that
HtrA/DegP purifies with other proteins bound [25]. The CtHtrA
mutation data in this study, especially the mutations in the PDZ1
cleft, demonstrate that I365N and L302D are clearly important in
the oligomerisation process. The L302D was unable to assemble
into oligomers under any of the conditions tested, while I365N
exhibited reduced 24-mer formation compared with the wild-type
protein. The reduced protease activity and partially conserved
oligomerisation activity observed for these two mutations are
consistent with the previously reported role of these residues for E.
coli DegP [18]. R299W and R299W/R373A, which reside in the
PDZ1:protease interface, oligomerised to 24-mers when incubated
with the activator, similar the wild-type protein. Thus, the PDZ1
cleft is critical for oligomer formation of CtHtrA, which is
consistent with the previous findings for DegP [18].
CtHtrA incubation with insulin, a previously demonstrated in
vitro chaperone substrate of CtHtrA [3], resulted in 24-mer and
higher molecular weight forms. These results indicate that
oligomerisation activity is also important for chaperone substrates.
However, the proteins with PDZ1 cleft or PDZ1:protease interface
mutations did not oligomerise when incubated with insulin. The
R299W/R373A mutant remained mainly as hexamer when
incubated with insulin, unlike when it was incubated with the
activator peptide and formed a 24-mer. This is in contrast to wild-
type CtHtrA which formed detectable 24mers when incubated
with either insulin or with Act1. These observations indicate that
Figure 4. The PDZ domain functions in CtHtrA activation by
Act1. A. Modelled PDZ- protease domain (dark blue) interface showing
the conserved salt bridge via R299 – D169 and a putative stabilizing salt
bridge via R373 – D193. B. PDZ1 putative activator cleft showing
residues R299, L302 and I365. C. Activity of CtHtrA wild-type, I365D,
R373A and R299W/R373A mutants against Bcas1 in the presence (grey;
120 mM) and absence of Act1 (black).
doi:10.1371/journal.pone.0024547.g004
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the PDZ1:protease interface is critical for the formation of
oligomers when a protein (chaperone substrate) is the activator
but does not impact on oligomer formation when the activator is a
peptide. This may be simply due to the difference in size, i.e.
insulin is two longer polypeptide chains, whereas Act1 is a 13-mer
peptide. This is consistent with the previous finding that different
sized activators triggered different sized oligomers for DegP
(peptides activated 12-mer versus full length ß-casein activated 24-
mer) [33]. However, since wild-type CtHtrA did form 24-mer in
the presence of both peptide and protein there may be subtle
differences in the activation mechanism from that reported for
DegP. This implies that these residues or the role of these residues
for the activated oligomers structural conformation, are important
specifically for chaperone substrates for CtHtrA. This is the first
time these residues have been identified to function for any DegP
oligomer formation. This data may suggest that HtrA protein
activation for polypeptide fragments (such as those which would be
present during protein stress) could be different than the activation
in response to full length proteins such as insulin. Similarly to the
findings here, DegP has been demonstrated to be activated in the
presence of two short peptide fragments (activator and substrate)
or polypeptide fragments long enough to activate and be cleaved
(such as those previously reported in the model termed the
molecular ruler [25]). However, the differences observed for the
PDZ:protease interface mutants activation when triggered with
insulin is unique. This in vitro model may therefore providing clues
on how this multi-tasking family of proteins distinguishes between
proteolysis and chaperone substrates.
Figure 5. CtHtrA is activated to form 24-mer multimeric complexes which are impacted by mutations in the PDZ1 domain. The figure
shows glutaraldehyde crosslinked protein samples prepared by oligomerisation assays which have been separated on 3–8% TrisAcetate gels prior to
silver staining. The different multimeric forms of the protein are indicated to the right and the molecular weights indicated on the left (High
molecular weight marker, Invitrogen). A. (protein only): 1. CtHtrA 09, 2. CtHtrA 109, 3. R299W 109, 4. L302N 109, 5. R373A 109, 6. I365D 109, 7. R299W/
R373A 109. B. Protein with Act1 109: 1. CtHtrA, 2. R299W, 3. L302N, 4. R373A, 5. I365D, 6. R299W/R373A. C. Protein with Insulin 109: 1. CtHtrA, 2.
R299W, 3. R373A, 4. L302N, 5. I365D, 6. R299W/R373A. # This picture is constructed from a single gel, only that the molecular weight marker lane has
been removed from the middle of the gel image for consistency with the other gels.
doi:10.1371/journal.pone.0024547.g005
Figure 6. Chlamydia trachomatis major outer membrane protein (MOMP) induces CtHtrA oligomerisation and protease activation.
A. Alignment of Act1, Act2, and PyKinC (control cytoplasmic enzyme) with C-terminal sequence of all outer membrane b-barrels in Chlamydia
trachomatis L2 (note: ompA is MOMP). Residue numbers are indicated below the alignment with 1 being the most C-terminal residue. The alignment
was performed in ClustalX with the default colour scheme hydrophobic: WLVIMAFC (blue), cysteine: C (pink), small: G (orange) cyclic: P (yellow), Polar
hydrophilic: TSNQ (green), Polar Aromatic: HY (cyan), Acidic: ED (magenta), Basic: KR (red). B. Oligomerisation of CtHtrA after 10 mins incubation with
MBP-MOMP, MBP-MOMP peptides, PmpC peptide, Ctl0043 peptide, and pyruvate kinase C peptide (PyKinC). C. CtHtrA proteolysis of Bcas1 (rate y-
axis) with each of the activators (indicated on x-axis).
doi:10.1371/journal.pone.0024547.g006
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To provide clues to in vivo targets of CtHtrA, peptides
containing the consensus sequence for outer membrane ß-barrel
assembly were tested for activation of oligomerisation. C.
trachomatis outer membrane protein (MBP-MOMP), tryptic
peptides of the same protein, and peptides corresponding to C-
terminal sequences of other C. trachomatis outer membrane proteins
were all examined. The peptides from the outer membrane
proteins, especially PmpC, were able to trigger 12-mer but not 24-
mer formation. These 12-mers may still be a chaperone form and
possibly these may have some relevance to the previously reported
lipid bowl chaperone structure (Shen et al., 2008). However, as we
have previously experimentally validated that insulin is a CtHtrA
chaperone substrate, and we demonstrate here that insulin triggers
CtHtrA 24-mer, we can only confidently assign a chaperone
function to the 24-mers. The full length MOMP protein (and not
the peptides resulting from the tryptic digest of the same protein)
was the most efficient trigger of 24-mer assembly and increased
proteolysis (other than Act1). Thus MOMP, an important outer
membrane ß-barrel protein for Chlamydia, is potentially an in vivo
chaperone substrate of CtHtrA.
The combined findings from this study have proven that CtHtrA
can be allosterically activated and that this activation involves
formation of protein oligomers. The major finding from this study is
that the PDZ1:protease interface and the PDZ1 cleft residues have
distinct roles in the formation of higher order oligomers after
binding of CtHtrA to chaperone or proteolysis substrates. This is the
first evidence implying that these two regions (PDZ1 cleft or
PDZ1:protease interface) may differentially facilitate or regulate the
oligomer formation for any DegP or HtrA. Regardless of this
potential regulatory function, this study has revealed novel residues
important for the activation mechanism of C. trachomatis CtHtrA.
Materials and Methods
Bacterial cultures
E. coli JM109 was used for all cloning and genetic manipula-
tions. E. coli BL21 (DE3) was transformed with the protein
expression plasmids and used for protein expression. E. coli was
routinely cultured on LB broth or plates (1 L: 10 g NaCl, 5 g
Yeast Extract, 10 g tryptone, pH 7.2) (1.5% w/v agar) with
Ampicillin (where required) at 100 mg/ml.
Site directed mutagenesis
The pETHtrA and pETS247A purified plasmid DNA was used
as the template for the site directed mutagenesis PCRs as
previously described [3]. The site directed mutagenesis PCRs
were conducted using the QuickChange II site directed mutagen-
esis kit (Stratagene), in accordance with the provided instructions.
A number of the site directed mutants were alternatively generated
using Pfu DNA polymerase (Promega) as the PCR polymerase (5-
phosphorylated primers) followed by Dpn1 digest of the template
DNA for 2 h at 37uC, overnight incubation with T4 DNA Ligase
(Promega), prior to transformation into JM109. The primers used
for site directed mutagenesis are listed in Table S1. All plasmids
were confirmed to contain the expected mutation with no other
introduced errors in the coding sequence by sequencing prior to
transformation into BL21 (DE3) for protein expression.
Protein expression and purification
The protein expression and purification methods for CtHtrA
have been previously reported [3]. Briefly, BL21 (DE3) pETHtrA
cultures were grown at 30uC until an O.D. 600(nm) of 0.6 was
reached. The protein expression was induced with 0.5 mM IPTG
and the cultures were grown for a further 150 min prior to
harvesting the cells. The cultures were then lysed by sonication,
and the unlysed cells were removed by centrifugation at 40006 g
for 12 min at 4uC. The His-tagged protein was then purified from
the cellular lysates using Talon Resin (Clontech, Australia), as per
the manufacturer’s instructions. These conditions were used for
the expression and purification of all site directed mutant proteins
reported in this study. The purified proteins were examined by
polyacrylamide gel electrophoresis to ensure homogeneity was
observed and Coomassie staining prior to use in protease assays.
The MBP-MOMP protein used in the oligomerisation assay was
kindly supplied by Mr Connor O’Meara. The protein was
recombinantly expressed in E. coli and purified using established
protocols [28]. The protein has an N-terminal MBP sequence and
C. muridarum MOMP, the C-terminal sequence of this MOMP (last
13 residues, is 100% conserved with C. trachomatis L2). MBP-
MOMP was reduced, denatured, and digested to completion using
trypsin. MOMP tryptic fragments were produced by reducing
purified MOMP (1 mg/ml) in PBS with 5 mM DTT (Merck) for
1 h at 65uC followed by carboxyamidomethylation with 25 mM
iodoacetamide for 30 min (SigmaAldrich, Australia) in the dark at
room temperature. The reduced and alkylated protein was then
digested with sequencing grade trypsin (Promega, Australia) for
18 h at 37uC at 1:100 trypsin:MOMP mass ratio. Digestion was
stopped by heat deactivating trypsin for 2 h at 85uC and the
reduction and carboxyamidomethylation repeated. The final
peptide mixture was C18 purified using Waters SepPak (1 ml)
columns according to manufacturer’s instructions. Eluted peptides
were vacuum concentrated to dryness in a Speedivac before
reconstituting in MilliQ water for further use.
Protease assays
The purified recombinant protein was examined by Coomassie
stained polyacrylamide gels and activity was checked using ß-
casein cleavage assays prior to use in peptide assays. Briefly, this
involved incubating 2 mg of the protease with 10 mg of ß-casein in
50 mM Tris pH 7.0, 20 mM MgCl2 for 2 h prior to examining
the assays by SDS PAGE (ß-casein and protease only controls
were always conducted). Protease assays using peptides were
conducted using custom synthesised peptides (Mimotopes). The
peptides were purified to 95% purity (or greater) and were
typically resuspended in 50% isopropanol, although some peptides
required 100% DMSO. Protease assays using pNA labelled
peptides were conducted using the xMARK Microplate spectro-
photometer (Bio-Rad) at 405 nm, incubated at 37uC, with a
reading taken every 10 s for 30 min. The maximum slope over a
minimum of 8 readings was used for the data analysis. Other
peptides were labelled with 7-methoxycoumarin-4-acetic acid
(MCA, fluorophore) and 2,4-dinitrophenyl (DNP, quencher). The
protease assays using these peptides were conducted in black plates
at 37uC using the POLARstar Optima (BMG Labtech). The
assays were excited at 340 nm and emission was detected at
405 nm with a gain of 1000, the assays were monitored every 20 s
or at the minimum cycle time for up to 40 min. The Omega
software was used to calculate the maximum rate from a minimum
of 6 time points for each assay. The REPLi library of peptides
(Mimotopes, Melbourne, Australia) was also assayed with CtHtrA
in the POLARstar Optima using similar assay conditions to those
described above. Substrate only and protease only assay controls
were conducted for every experiment and protease assays were
typically conducted in triplicate on at least two different days. The
assay results shown are the maximal rate observed from three or
more different assays and adjusted for protein concentration. The
assay results shown for the fluorescent compounds have been
normalised for the amount of fluorescent emission detected using a
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standard curve of known concentrations of the MCA fluorophore
under the identical assay conditions. All of the peptides used in this
work were synthesised commercially to 95% purity or greater
(Mimotopes, Melbourne, Australia). All protease assays were
conducted minimally in duplicate on three separate occasions.
Oligomerisation Assays
The oligomerisation of HtrA into 12- and 24-mer complexes
has been independently detected for E. coli HtrA (DegP). The
oligomerisation of HtrA (DegP) was triggered by peptides from
digested ß-casein [18]. Assays to detect whether CtHtrA and site
directed mutant protein oligomerisation was triggered by sub-
strates were conducted essentially as previously described (Merda-
novic et al., 2010). Briefly, 2 mg/ml protein solutions in 100 mM
sodium phosphate buffer pH 7.0 were pre-incubated to the
required temperature. The ligands (activator peptide, or insulin)
were added and at 10 min, and the proteins were fixed using 0.5%
glutaraldehyde. Samples were fixed at room temperature for
2 min prior to addition of 1 M Tris pH 7.5 to remove any excess
glutaraldehyde. Samples were incubated for another 10 min at
room temperature prior to addition of SDS PAGE reducing
loading buffer. The protein samples were examined on 3–8%
TrisAcetate gradient polyacrylamide gels (Novex, Invitrogen) by
silver staining [34]. The proteins used in this study were not
initially denatured by treatment with urea as, the refolding,
formation of oligomers, and protease activity was never success-
fully detected with denatured CtHtrA. All assays were conducted
in duplicate on three separate occasions with at least two gels of
each experiment completed for each assay condition.
Molecular Modelling of the CtHtrA structure
The crystal structures of activated E. coli DegS (pdb1soz and
pdb2r3y) [35,36] and the inactive E. coli DegP hexamer (pdb1ky9)
[17] were used to generate homology models of CtHtrA (accession
no. P18584). Models were generated using Modeller9v6 [37] based
on sequence alignments generated using use T-coffee server [38].
Proteomic identification of CtHtrA cleavage sites
The proteome-derived database searchable peptide library
approach or Proteomic Identification of protease Cleavage Sites
(PICS) was used to identify CtHtrA cleavage sites in a naturally
sourced peptide library, as previously described by Schilling and
Overall (2008) with some minor modifications. CtHtrA, 12 mM
Act1, and peptide libraries were combined (100 mM HEPES
pH 7.0 as the reaction buffer). All recovered peptides were analysed
by LC/MS/MS at the Institute for Molecular Biosciences at the
University of Queensland using a QStar Elite. All data was
converted to mzXML using mzwiff and searched using Mascot and
Tandem against the uniprot database (Jan 2010: Human and
Mouse with included reverse decoy database). Data were searched
using a precursor ion tolerance of +/22.2 Da,MS/MS tolerance of
0.4 Da, fixed modifications including dimethylation of lysine,
sulfamine modification of peptide N-termini, carboxyamidomethy-
lation of cysteines and variable oxidation of methionines. All search
results were analysed using the trans-proteomic pipeline (v4.4)
combining both searches using the interprophet parser and
corrected for false-discovery rate of less than or equal to 0.05. All
raw data and mass spectra can be made available on request.
MS and MS-MS analysis of peptide cleavage products
Bcas1 and Act1 peptides (150 mM concentration) digested with
CtHtrA (71 mg) were analysed by online LC/MS/MS using a
QStar Pulsar I (Applied Biosystems) in independent data
acquisition mode. Data acquired were converted into mzXML
format using proteowizard (v2) and searched using (v1, the global
proteome machine, ftp://ftp.thegpm.org/fasta/cRAP), against
CtHtrA and Act1 and Bcas1 peptide sequences with an included
decoy database of the reverse sequence for each protein. The
search also included potential mass modifications accounting for
the additional quencher/fluorophore moieties on the N and C
peptide termini, respectively. Matches with an expected ratio of
,1 were considered identified. All raw data and mass spectra can
be made available on request.
Supporting Information
Figure S1 A. Weblog of the PICS results. B. A full listing of all
PICs data (listed below).
(DOCX)
Figure S2 Results of protease assays using the REPLI
Library all wells which has detectable substrates for
CtHtrA are shown on the graph. The relative rate of
fluorescent accumulation per min per ug of CtHtrA is shown on
the Y axis. The well descriptions are indicated on the x axis. The
wells contain 4–8 peptides with similar functional residues
grouped, with a single residue variation between the two listed
on each peptide. The peptides have a fluorophore (MCA) and
quencher (Lys-DNP) with two trimers of glycine on each side of
the variant trimer of amino acids in the middle (variant trimer
ranges are indicated on the x axis).
(DOCX)
Figure S3 Characterisation of Bcas1 cleavage by
CtHtrA. A. LC/MS plot of Bcas1 alone. B. B LC/MS plot of
Bcas1 cleaved with CtHtrA shows addition of ions compared to
Bcas1 alone. C. MS/MS of product ion 552.37 m/z, 26.3 min
(circle in B) matches internal fragment of Bcas1.
(DOCX)
Figure S4 Characterisation of protease specificity in the
presence of the activator peptide using PICS. A. Web Logo
summary of all peptide cleavage sites identified during PICS
protocol with CtHtrA and Act1. B. The table below lists all
peptide cleavage sites identified during PICS protocol with
CtHtrA and Act1.
(DOCX)
Table S1 Primers and amplification conditions used for
site directed mutagenesis PCR.
(DOCX)
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